1. Osteoclastogenesis in Bone Remodeling {#sec1-ijms-21-03646}
========================================

Bone remodeling is balanced by the coordinated activities of osteoclastic resorption and osteoblastic formation \[[@B1-ijms-21-03646]\]. Imbalanced bone remodeling leads to bone diseases including osteoporosis, periodontitis and rheumatoid arthritis, which are characterized by enhanced osteoclast activity. In other words, an excessive increase in osteoclast differentiation and bone resorption gives rise to various bone-resorptive diseases \[[@B2-ijms-21-03646]\]. Osteoclasts are the cells responsible for bone resorption. These large multinucleated cells originate from the monocyte/macrophage hematopoietic lineage \[[@B3-ijms-21-03646],[@B4-ijms-21-03646]\]. Osteoclast differentiation depends on two essential cytokines, receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) \[[@B5-ijms-21-03646],[@B6-ijms-21-03646],[@B7-ijms-21-03646]\]. M-CSF is involved in the proliferation and survival of osteoclast precursors and RANKL induce osteoclast differentiation through binding to its receptor RANK and subsequent activation of nuclear factor of activated T cells (NFATc1), a master transcription factor required for osteoclast differentiation \[[@B8-ijms-21-03646]\]. Osteoclasts are formed by the fusion of osteoclast precursor cells. Cellular fusion is an essential element in osteoclast development that results in the formation of multinucleated giant cells responsible for bone resorption activity. This process is called osteoclastogenesis. To resorb bone, osteoclasts attach to the bone surface, form a "ruffled border" and dissolve bone mineral by massive secretion of acidic elements \[[@B3-ijms-21-03646]\].

2. The Role of Calcium (Ca^2+^) Signaling in Osteoclastogenesis {#sec2-ijms-21-03646}
===============================================================

Ca^2+^ signaling in osteoclasts is important for multiple cellular functions, including proliferation, differentiation, gene transcription and bone resorption \[[@B9-ijms-21-03646]\]. Ca^2+^ is released from intracellular stores, or enters the cell via plasma membrane ion channels \[[@B10-ijms-21-03646]\]. RANKL-mediated signaling in osteoclasts is the initial step of bone resorption initiation. RANK-bound RANKL induces activation of the tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) \[[@B11-ijms-21-03646]\], subsequently involved in the activation of mitogen-activated protein kinases (MAPKs), nuclear factor-κB (NF-κB), and a component of activator protein-1 (AP-1) \[[@B8-ijms-21-03646],[@B12-ijms-21-03646],[@B13-ijms-21-03646]\]. Activated NF-κB induces NFATc1 transcription to differentiate osteoclasts \[[@B6-ijms-21-03646],[@B14-ijms-21-03646]\]. RANKL also stimulates phospholipase Cγ (PLCγ) during the early stages of osteoclastogenesis. Activated PLCγ produces inositol 1, 4, 5-triphosphate (IP~3~) in the cytosol. Son et al. \[[@B15-ijms-21-03646]\] reported that RANKL-mediated activation of PLC induces an increase of cytosolic IP~3~ levels, which increases intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) through inducing its release from the endoplasmic reticulum (ER). Ca^2+^ influx through store-operated Ca^2+^ entry (SOCE) and transient receptor potential (TRP) channels causes RANKL-induced \[Ca^2+^\]~i~ oscillations during osteoclastogenesis \[[@B16-ijms-21-03646],[@B17-ijms-21-03646],[@B18-ijms-21-03646],[@B19-ijms-21-03646]\]. TRP channels are involved in not only extracellular but also intracellular Ca^2+^ balance in osteoclasts \[[@B20-ijms-21-03646]\]. Ca^2+^ release and reuptake into the ER stores is also necessary for \[Ca^2+^\]~i~ oscillations. Sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA) transports Ca^2+^ from the cytosol into the ER, and SERCA activity is also essential for \[Ca^2+^\]~i~ oscillations. Disruption of SERCA2 expression impairs RANKL-induced \[Ca^2+^\]~i~ oscillations \[[@B21-ijms-21-03646]\]. Furthermore, RANKL induces a reactive oxygen species (ROS) pathway and causes long lasting \[Ca^2+^\]~i~ oscillations \[[@B22-ijms-21-03646]\]. Cytosolic Ca^2+^ binds to calmodulin (CaM), which results in the activation of CaM-dependent enzymes such as the phosphatase calcineurin \[[@B23-ijms-21-03646]\]. Activated calcineurin dephosphorylates serine residues in NFATc1, resulting in translocation of NFATc1 into the nucleus \[[@B24-ijms-21-03646],[@B25-ijms-21-03646]\]. A recent study using Homer2 and Homer3 (Homer2/3) double-knockout (DKO) mice showed that Homer proteins regulate NFATc1 function through interaction with calcineurin to regulate RANKL-induced osteoclastogenesis \[[@B26-ijms-21-03646]\]. Thus, increased \[Ca^2+^\]~i~ is a fundamental process mediating osteoclastogenesis ([Figure 1](#ijms-21-03646-f001){ref-type="fig"}). In this review, we focused on modulation of Ca^2+^ signaling through Ca^2+^ influx via TRP channels and highlighted the diverse compounds, involved in the Ca^2+^ -mediated signaling pathway, in osteoclastogenesis.

3. Transient Receptor Potential (TRP) Channels in Osteoclast {#sec3-ijms-21-03646}
============================================================

Cytosolic Ca^2+^ modulation is crucial in osteoclastogenesis. TRP channels are widely expressed in several mammalian tissues and involved in diverse physiological processes such as differentiation, proliferation, and apoptosis \[[@B27-ijms-21-03646],[@B28-ijms-21-03646]\]. Several studies have focused on TRP channels as Ca^2+^-influx channels in RANKL-induced osteoclastogenesis. Generally, TRP channels are non-selective cation channels and are divided into six subfamilies: canonical (TRPCs), vanilloid (TRPVs), melastatin (TRPMs), mucolipin (TRPMLs), polycystins (TRPPs), and ankyrin (TRPA) \[[@B29-ijms-21-03646]\]. Among the TRP channels, TRPV2 \[[@B30-ijms-21-03646]\], TRPV4 \[[@B31-ijms-21-03646]\], and TRPV5 \[[@B32-ijms-21-03646]\] contribute to intracellular Ca^2+^ signaling in osteoclast differentiation. TRPC1 also regulates osteoclast differentiation through SOCE \[[@B33-ijms-21-03646]\]. This section discusses the roles of TRPC, TRPV, and TRPML channels in osteoclastogenesis.

3.1. TRPC {#sec3dot1-ijms-21-03646}
---------

Mildly enhanced bone mass was observed in TRPC1 null mice and its effect was revealed only in mice lacking inhibitor of MyoD family isoform a (I-mfa) \[[@B33-ijms-21-03646]\]. TRPC1 binds I-mfa \[[@B34-ijms-21-03646]\]. Trpc1 and I-mfa functionally interact to regulate the early differentiation stage of the osteoclast through antagonistic regulation of SOCE. Although there are limited studies on TRPC, the modulation of the Ca^2+^ release-activated Ca^2+^ current (I~CRAC~) by TRPC1, and I-mfa is crucial for NFATc1 activation and subsequent osteoclast differentiation \[[@B33-ijms-21-03646]\].

3.2. TRPV {#sec3dot2-ijms-21-03646}
---------

TRPV family members act as sensory channels for receptor-operated Ca^2+^ influx and are critically involved in the regulating of osteoclast differentiation \[[@B20-ijms-21-03646]\]. The TRPV family consists of six members, TRPV1--TRPV6, composed of six transmembrane domains that form a cation-permeable pore \[[@B35-ijms-21-03646],[@B36-ijms-21-03646],[@B37-ijms-21-03646]\].

Among the TRPV family members, TRPV1 is a non-selective cation channel activated by various stimuli such as heat, noxious stimuli, low pH, and numerous chemicals \[[@B38-ijms-21-03646]\]. The physiological role of TRPV1 in bone biology was addressed one decade ago. TRPV1 is expressed in osteoclasts and promotes their differentiation \[[@B39-ijms-21-03646]\]. Human osteoclast expresses functional TRPV1, as well as the cannabinoid receptors type 1 and 2 (CB1/CB2). The involvement of both receptors is controversial. Expression levels of TRPV1 are enhanced in osteoclasts derived from osteoporotic subjects, whereas CB2 are reduced \[[@B40-ijms-21-03646]\]. More recently, TRPV1 desensitization and/or CB2 stimulation were found beneficial for reducing osteoclast over-activity \[[@B41-ijms-21-03646],[@B42-ijms-21-03646]\]. There are several reports showing that application of the TRPV1 agonist capsaicin suppresses LPS-induced prostaglandin E2 (PGE2) production in osteoblasts and suppressed LPS-induced osteoclast formation \[[@B39-ijms-21-03646],[@B43-ijms-21-03646]\]. On the other hand, the TRPV1 antagonist capsazepine inhibits bone formation and bone resorption activity of osteoclasts in OVX mice \[[@B44-ijms-21-03646]\]. \[6\]-Gingerol, a major constituent of ginger, augments osteoclast function via TRPV1 and induces bone loss in adult ovary-intact mice \[[@B45-ijms-21-03646]\]. Zoledronic acid is nitrogen containing bisphosphonate that inhibit bone resorption. Effects of the Zoledronic acid were antagonized by capsazepine supporting the involvement of TRPV1 channel in osteoblastogenesis and mineralization, but this mechanism is not effective in osteoclasts lacking the TRPV1 \[[@B46-ijms-21-03646]\]. Sirtuin 1 (SIRT1), also known as nicotinamide adenine dinucleotide (NAD^+^)-dependent lysine deacetylase, directly inhibits the osteoclast differentiation by inhibiting ROS generation and TNF-α-mediated TRPV1 channel activation \[[@B47-ijms-21-03646]\]. In addition, TRPV1, as a pain receptor, is expressed in peripheral sensory nerves \[[@B48-ijms-21-03646],[@B49-ijms-21-03646]\]. A pathological role of TRPV1 has been revealed in both osteoporosis and osteoarthritis \[[@B41-ijms-21-03646],[@B50-ijms-21-03646]\].

TRPV2 is closely related to TRPV1 \[[@B38-ijms-21-03646],[@B51-ijms-21-03646]\]. TRPV2 is expressed in RANKL-treated RAW264.7 cells and TRPV2-mediated spontaneous \[Ca^2+^\]~i~ oscillations activate NFATc1 and promote osteoclast differentiation \[[@B30-ijms-21-03646]\]. More recently, TRPV2 was found to regulate RANKL-dependent osteoclastic differentiation through the Ca^2+^-calcineurin-NFATc1 signaling pathway in multiple myeloma (MM) patients \[[@B52-ijms-21-03646]\].

TRPV4 also plays an essential role in osteoclast differentiation \[[@B31-ijms-21-03646]\]. It is known as a mechano- and osmo-sensor \[[@B53-ijms-21-03646],[@B54-ijms-21-03646]\], and localizes to the basolateral membranes of mature osteoclasts \[[@B31-ijms-21-03646]\]. TRPV4-mediated Ca^2+^ influx and intracellular Ca^2+^ signaling activate NFATc1 and induce osteoclast differentiation and resorption activity \[[@B31-ijms-21-03646],[@B55-ijms-21-03646]\]. A protein--protein interaction between TRPV4 and myosin IIa regulates Ca^2+^/CaM signaling, which supports the migration and fusion of osteoclast precursors \[[@B55-ijms-21-03646]\]. In addition, the TRPV4-specific antagonist, RN1734, inhibits osteoclast formation, whereas the TRPV4-specific agonist 4-α-PDD enhances osteoclast formation under mild acidic conditions \[[@B56-ijms-21-03646],[@B57-ijms-21-03646]\]. Stromal interaction molecule 1 (STIM1)-mediated SOCE is involved in fluid shear stress (FSS)-induced \[Ca^2+^\]~i~ oscillations at the early differentiation stage of osteoclasts, whereas TRPV4 is highly associated with the Ca^2+^ response at the late stage of differentiation under FSS simulation \[[@B58-ijms-21-03646]\]. TRPV4 knockdown significantly suppresses osteoclast differentiation and osteoporosis by inhibiting the Ca^2+^-calcineurin-NFATc1 pathway \[[@B59-ijms-21-03646]\].

TRPV5, a highly selective Ca^2+^ channel, is activated by low \[Ca^2+^\]~i~ \[[@B60-ijms-21-03646]\]. It is predominantly located on the ruffled borders of the membranes of resorbing osteoclasts \[[@B32-ijms-21-03646]\]. TRPV5 knockout mice showed increased osteoclast numbers and reduced trabecular and cortical bone thickness \[[@B61-ijms-21-03646]\]. In contrast, TRPV5 knockout mice had impaired osteoclastic function in vivo \[[@B32-ijms-21-03646]\]. Although controversial, these findings suggest that TRPV5 plays an important role in osteoclastic function, again demonstrating the significance of Ca^2+^ influx in mature osteoclasts. In addition, small interfering RNA (siRNA) knockdown of TRPV5 completely inhibits RANKL-induced Ca^2+^ influx at the late differentiation stage of osteoclasts in vitro and enhances bone resorption activity in human osteoclasts \[[@B20-ijms-21-03646],[@B62-ijms-21-03646]\]. The lack of estrogen leads to osteoporosis. Estrogen inhibits osteoclast differentiation and bone resorption activity by increasing TRPV5 expression in postmenopausal osteoporosis \[[@B63-ijms-21-03646]\]. Song et al. also demonstrated that estrogen increases TRPV5 expression through the interaction of the estrogen receptor α (ERα) in RAW 264.7 cells. Furthermore, NF-κB binds to the putative site on the *trpv5* promoter, and TRPV5 is regulated by NF-κB \[[@B64-ijms-21-03646]\]. Thus, TRPV5 contributes to the processes of estrogen-mediated osteoclast formation, bone resorption activity, and osteoclast apoptosis. A recent study showed that vitamin D (1,25(OH)~2~D~3~) inhibits TRPV5 expression at the early stage of osteoclastogenesis by suppressing osteoclast differentiation \[[@B65-ijms-21-03646]\].

3.3. TRPML {#sec3dot3-ijms-21-03646}
----------

The TRPML family has three members: TRPML1, TRPML2, and TRPML3. Among these, TRPML1 is a non-selective cation channel that permeates Ca^2+^ \[[@B66-ijms-21-03646]\]. TRPML1 is a Ca^2+^-permeable channel in lysosomes and plays vital roles in lysosomal trafficking and functions \[[@B67-ijms-21-03646]\]. Erkhembaatar et al. \[[@B68-ijms-21-03646]\] showed that deleting TRPML1 inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations, which reduces osteoclastogenesis and bone remodeling.

4. Diverse Compounds Modulating Ca^2+^ Signaling in Osteoclastogenesis {#sec4-ijms-21-03646}
======================================================================

Osteoclasts are responsible for bone resorption and are therefore considered targets of anti-osteoporosis therapies. Novel treatment strategies aimed at preventing excessive bone resorption have been studied \[[@B69-ijms-21-03646]\]. The study of antiresorptive agents derived from diverse compounds has become a recent topic of interest. The aim of this section is to summarize the current knowledge on diverse compounds that regulate osteoclast differentiation by modulating Ca^2+^ signaling. Thus, in this section, we mentioned by listing diverse compounds depending on their mode of action. [Table 1](#ijms-21-03646-t001){ref-type="table"} and [Figure 2](#ijms-21-03646-f002){ref-type="fig"} summarize diverse compounds that regulate Ca^2+^ signaling in osteoclastogenesis.

4.1. Ca^2+^-Calcineurin-NFATc1 (CCN) Pathway {#sec4dot1-ijms-21-03646}
--------------------------------------------

### 4.1.1. KMUP-1 {#sec4dot1dot1-ijms-21-03646}

KMUP-1 (7-\[2-\[4-(2-chlorophenyl)piperazinyl\]ethyl\]-1,3-dimethylxanthine), a chemical synthetic xanthine-based derivative, effectively suppresses RANKL-induced osteoclast differentiation in vitro, and also attenuated ovariectomized (OVX)-induced osteoclast differentiation and prevented bone resorption in vivo \[[@B18-ijms-21-03646]\]. Especially KMUP-1 inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations, and subsequently, inhibits calcineurin-NFATc1 signaling \[[@B70-ijms-21-03646]\].

### 4.1.2. Zinc {#sec4dot1dot2-ijms-21-03646}

It has been shown that zinc, an important trace element, inhibits osteoclast differentiation by suppressing the Ca^2+^-calcineurin-NFATc1 signaling pathway in vitro and in vivo \[[@B19-ijms-21-03646]\]. Specifically, zinc inhibits calcineurin activity but not expression and RANKL-induced \[Ca^2+^\]~i~ oscillations, without decreasing PLCγ phosphorylation. In addition, it was proposed that zinc inhibits calcineurin in the early stage of osteoclast differentiation and \[Ca^2+^\]~i~ oscillations in the middle or late stage of osteoclast differentiation \[[@B71-ijms-21-03646]\].

### 4.1.3. Praeruptorin A {#sec4dot1dot3-ijms-21-03646}

Praeruptorin A is isolated from the dried root of *Peucedanum praeruptorum* Dunn. It also has anti-osteoclastogenic activity by inhibiting \[Ca^2+^\]~i~ oscillations without decreasing PLCγ phosphorylation \[[@B72-ijms-21-03646]\].

### 4.1.4. Cyanidin {#sec4dot1dot4-ijms-21-03646}

Cyanidin, a particular type of anthocyanidins, is the sugar-free counterpart of anthocyanins. Anthocyanins are reddish pigments widely spread in colored fruits and vegetables \[[@B97-ijms-21-03646],[@B98-ijms-21-03646]\]. Cyanidin chloride inhibits RANKL-induced osteoclast formation and osteoclast resorptive activity in vitro and protects against OVX-induced bone loss in vivo. Furthermore, cyanidin chloride impairs RANKL-induced \[Ca^2+^\]~i~ oscillations, which leads to the suppression of the activation of NFATc1 in cultured primary bone marrow-derived macrophages (BMMs) \[[@B73-ijms-21-03646]\]

### 4.1.5. Lumichrome {#sec4dot1dot5-ijms-21-03646}

Lumichrome is a natural metabolite of riboflavin, a member of the B family of vitamins, and has been shown to have a beneficial effect on bone formation \[[@B99-ijms-21-03646],[@B100-ijms-21-03646]\]. Chuan et al. \[[@B74-ijms-21-03646]\] found that lumichrome inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations in BMMs. Furthermore, lumichrome suppresses NFATc1, NF-κB, and MAPK signaling activation and decreases bone loss in OVX-mice by inhibiting osteoclastogenesis.

### 4.1.6. Asiaticoside {#sec4dot1dot6-ijms-21-03646}

*Asiaticoside*, a natural compound, is extracted from *Centella asiatica* and is a member of the triterpenoid family \[[@B101-ijms-21-03646]\]. It significantly inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations and NFATc1 expression in BMMs. Therefore, *Asiaticoside* suppresses the differentiation and function of the osteoclast via inhibiting the NF-κB and NFATc1 pathways \[[@B75-ijms-21-03646]\].

4.2. PLCγ-Ca^2+^-NFATc1 (PCN) Pathway {#sec4dot2-ijms-21-03646}
-------------------------------------

### 4.2.1. Oleanolic Acid Acetate {#sec4dot2dot1-ijms-21-03646}

Oleanolic acid acetate (OAA) is a compound isolated from *Vigna angularis* (azuki bean). Kim et al. \[[@B76-ijms-21-03646]\] have reported that OAA negatively regulates osteoclast differentiation by RANKL-induced PLCγ2 and \[Ca^2+^\]~i~ oscillations, which leads to NFATc1 activation. In vitro, OAA inhibits RANKL-induced osteoclast differentiation through PLCγ2-Ca^2+^-NFATc1 signaling. OAA administration also suppresses lipopolysaccharide (LPS)-induced bone loss in vivo.

### 4.2.2. Harpagoside {#sec4dot2dot2-ijms-21-03646}

Harpagoside (HAR), an iridoid glycoside isolated from *Harpagophytum procumbens* (devil's claw), inhibits \[Ca^2+^\]~i~ oscillations via inactivation of several kinases such as Bruton's tyrosine kinase (Btk), spleen tyrosine kinase (Syk), and PLCγ2, which leads to the suppression of RANKL-induced osteoclast differentiation \[[@B77-ijms-21-03646]\]. HAR also restored bone density in an LPS-induced, but not in an OVX-induced bone loss mouse model in vivo \[[@B77-ijms-21-03646]\].

### 4.2.3. Artesunate {#sec4dot2dot3-ijms-21-03646}

Artesunate is one of the effective clinical treatments for falciparum malaria \[[@B102-ijms-21-03646]\]. It suppresses RANKL-induced Ca^2+^ influx and calcineurin expression. Furthermore, phosphorylation of PLCγ1 is decreased by artesunate treatment in RANKL-stimulated RAW264.7 cells. Therefore, artesunate suppresses RANKL-induced osteoclast differentiation and function by inhibiting the PLCγ1-Ca^2+^-calcineurin-NFATc1 pathway \[[@B78-ijms-21-03646]\].

### 4.2.4. Methyl Gallate {#sec4dot2dot4-ijms-21-03646}

Methyl gallate (MG) is a polyphenolic compound that is known to have antioxidant \[[@B103-ijms-21-03646]\], antitumor \[[@B104-ijms-21-03646]\], anti-inflammatory \[[@B105-ijms-21-03646]\], and antimicrobial activities \[[@B106-ijms-21-03646]\]. MG is a dominant inhibitor of sodium and potassium ion channels in skeletal muscle cells \[[@B107-ijms-21-03646]\]. Baek et al. \[[@B79-ijms-21-03646]\] showed that MG attenuates RANKL-induced osteoclast differentiation by inhibiting both Akt (Protein kinase B) phosphorylation and intracellular Ca^2+^ influx mediated by Btk and PLCγ2.

### 4.2.5. Berberine Hydrochloride {#sec4dot2dot5-ijms-21-03646}

Berberine hydrochloride, an isoquinoline alkaloid, is found in many plants of the Berberidaceae families \[[@B108-ijms-21-03646]\]. It inhibits the activation of PLCγ1, and thereby, inhibits Ca^2+^ influx, which reduces intracellular Ca^2+^ concentration, and subsequently, inhibits osteoclast differentiation and bone destruction through suppression of the TRAF6-Ca^2+^-calcineurin-NFATc1 signaling pathway in LPS-stimulated RAW264.7 cells \[[@B80-ijms-21-03646]\].

### 4.2.6. Tatarinan N {#sec4dot2dot6-ijms-21-03646}

Tatarinan N (TN), a lignin-like component, is extracted from *Acorus tatarinowii Schott* \[[@B109-ijms-21-03646]\]. It attenuates RANKL-induced osteoclast differentiation via reducing NFATc1 and c-Fos expression as well as inhibiting the ERK1/2 or p38 signaling pathway. Besides, TN significantly reduces the elevation of intracellular Ca^2+^ concentration induced by RANKL and attenuates RANKL-induced phosphorylation of Btk and PLCγ2 in a dose-dependent manner in BMMs \[[@B81-ijms-21-03646]\].

### 4.2.7. Physalin D {#sec4dot2dot7-ijms-21-03646}

Physalin D is isolated from *Physalis alkekengi* L., known as "winter cherry", and grows in western Asia and Europe \[[@B110-ijms-21-03646]\]. Physalin D has been shown to have anti-inflammatory, antimalarial, and antinociceptive effects \[[@B110-ijms-21-03646],[@B111-ijms-21-03646],[@B112-ijms-21-03646]\]. Physalin D attenuates RANKL-induced \[Ca^2+^\]~i~ oscillations by inhibiting phosphorylation of PLCγ2 and blocks the downstream activation of Ca^2+^/calmodulin-dependent protein kinase (CaMK) type IV and cAMP-responsive element-binding protein (CREB) in BMMs. Moreover, physalin D protects RANKL-induced bone loss in vivo \[[@B82-ijms-21-03646]\].

4.3. Negative Regulation on Ca^2+^ Signaling {#sec4dot3-ijms-21-03646}
--------------------------------------------

### 4.3.1. Glechoma Hederacea {#sec4dot3dot1-ijms-21-03646}

*Glechoma hederacea* (GH), known as 'ground ivy' or 'creeping Charlie', is a perennial hairy herb of the mint family Lamiaceae. Hwang et al. \[[@B83-ijms-21-03646]\] have shown that GH induces a transient and large increase in \[Ca^2+^\]~i~, through the involvement of Ca^2+^ influx via voltage-gated Ca^2+^ channels (VGCCs), resulting in the abrogation of RANKL-induced \[Ca^2+^\]~i~ oscillations and the inhibition of NFATc1 expression in BMMs. However, GH-induced intracellular \[Ca^2+^\]~i~ elevation was independent of Ca^2+^ release from intracellular Ca^2+^ stores in BMMs. Taken together, these findings suggest that GH abrogates RANKL-induced \[Ca^2+^\]~i~ oscillations, inhibits NFATc1 expression, and reduces osteoclast differentiation by inactivating VGCCs.

### 4.3.2. Portulaca Oleracea {#sec4dot3dot2-ijms-21-03646}

*Portulaca oleracea* (PO), also known as verdolaga, red root, or pursley, has been widely used as traditional medicine. PO ethanol extract (POEE) has dual and contrary effects on RANKL-induced osteoclast differentiation. The POEE inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations and NFATc1 activation, while it enhances RANKL-induced osteoclast differentiation by reducing RANKL-mediated cytotoxicity. Erkhembaatar et al. \[[@B84-ijms-21-03646]\] proposed that RANKL-mediated cytotoxicity due to Ca^2+^ release from intracellular Ca^2+^ stores is attenuated by POEE, which leads to enhanced RANKL-induced osteoclast differentiation.

### 4.3.3. Methotrexate {#sec4dot3dot3-ijms-21-03646}

Methotrexate (MTX) is used to treat sarcoma, leukemia, and auto-inflammatory diseases such as rheumatoid arthritis \[[@B113-ijms-21-03646],[@B114-ijms-21-03646]\]. MTX inhibits osteoclast differentiation by inhibiting RANKL-induced Ca^2+^ influx in osteoclast progenitor cells \[[@B85-ijms-21-03646]\].

### 4.3.4. Xanthotoxin {#sec4dot3dot4-ijms-21-03646}

Xanthotoxin (XAT) is isolated from the seeds of a plant of the carrot family *Ammi majus* \[[@B115-ijms-21-03646]\]. XAT has been shown to have antitumor activity and antioxidant activity \[[@B116-ijms-21-03646],[@B117-ijms-21-03646]\]. Interestingly, XAT affects the intracellular Ca^2+^ levels in melanocytes, resulting in reorganization of actin stress fiber cytoskeleton \[[@B118-ijms-21-03646]\]. Dou et al. \[[@B86-ijms-21-03646]\] showed that XAT suppresses RANKL-induced \[Ca^2+^\]~i~ oscillations and the activation of downstream targets of Ca^2+^-CaMKK (Calmodulin-dependent protein kinase kinase)/Pyk2 (Proline-rich tyrosine kinase 2) signaling during osteoclast differentiation, resulting in the inhibition of NFATc1 and c-FOS in BMMs. In addition, an in vivo study showed that XAT treatment prevents bone loss and increases new bone formation in OVX-mice.

### 4.3.5. Sinomenine {#sec4dot3dot5-ijms-21-03646}

Sinomenine (SIN) is an alkaloid found in the roots and stems of *Sinomenium acutum*. SIN has been used for the treatment of rheumatoid arthritis (RA) in China \[[@B119-ijms-21-03646]\]. SIN dramatically reduces LPS-induced upregulation of intracellular Ca^2+^ in matured RAW264.7 cells. In addition, SIN decreases expression of osteoclast-specific genes and tumor necrosis factor-α (TNF-α) production, and inhibits LPS-induced osteolysis and osteoclast differentiation in vitro and in vivo \[[@B87-ijms-21-03646]\].

### 4.3.6. Dried Plum Fractions {#sec4dot3dot6-ijms-21-03646}

In preclinical trials, bone resorption is decreased by dietary supplementation with dried plum in ovariectomized rat and mouse models \[[@B120-ijms-21-03646],[@B121-ijms-21-03646]\]. Graef et al. \[[@B88-ijms-21-03646]\] showed that polyphenolic compounds in dried plums suppress intracellular Ca^2+^ signaling and MAPK signaling, resulting in the inhibition of NFATc1 expression, which reduces osteoclast differentiation in BMMs.

### 4.3.7. KN93 {#sec4dot3dot7-ijms-21-03646}

KN93 is an inhibitor of multifunctional Ca^2+^/CaMKs \[[@B122-ijms-21-03646]\]. It inhibits the formation and activation of the osteoclast. KN93 also downregulates the expression of NFATc1 and AP-1 protein family members in RANKL-stimulated RAW 264.7 cells. Furthermore, KN93 significantly decreases intracellular Ca^2+^ concentration in differentiated osteoclasts \[[@B89-ijms-21-03646]\].

### 4.3.8. Cajaninstilbene Acid {#sec4dot3dot8-ijms-21-03646}

Cajaninstilbene acid (CSA) is a bioactive compound derived from pigeon pea leaves \[[@B123-ijms-21-03646]\]. It suppresses osteoclast differentiation and bone resorption via inhibiting RANKL-induced ROS activity and \[Ca^2+^\]~i~ oscillations in RAW264.7 cells and BMMs. CSA also protects the bone loss of OVX- induced C57BL/6 mice \[[@B90-ijms-21-03646]\].

### 4.3.9. Methylglyoxal {#sec4dot3dot9-ijms-21-03646}

Methylglyoxal is derived from organic compounds and is a precursor of advanced glycation end products. Its formation involves several metabolic pathways \[[@B124-ijms-21-03646]\]. The formation of Methylglyoxal is increased in diabetic patients \[[@B125-ijms-21-03646]\]. Diabetes can give rise to a state of low bone turnover osteoporosis \[[@B126-ijms-21-03646]\]. The Methylglyoxal decreases \[Ca^2+^\]~I~, mitochondrial biogenesis, mitochondrial membrane potential, and glyoxalase I, resulting in the inhibition of RANKL-induced osteoclast differentiation and bone resorbing activity in RAW264.7 cells \[[@B91-ijms-21-03646]\].

### 4.3.10. Apocynin {#sec4dot3dot10-ijms-21-03646}

The catechol apocynin (APO) is used as a NADPH oxidase (NOX) inhibitor \[[@B127-ijms-21-03646]\]. Soares et al. \[[@B92-ijms-21-03646]\] evaluated the effects of APO on osteoclast differentiation. APO reduces \[Ca^2+^\]~i~ by blocking Ca^2+^ channels except two pore segment channel 2 (TPC2) and inositol 1,4,5-triphosphate receptor type 1 (IP~3~R1). TPC2 is a Ca^2+^-permeable channel expressed in lysosomes, and IP~3~R1 is a Ca^2+^ channel that mediates Ca^2+^ release from the ER, following IP~3~ stimulation. APO inhibits osteoclast differentiation by decreasing \[Ca^2+^\]~i~.

### 4.3.11. Loureirin B {#sec4dot3dot11-ijms-21-03646}

Loureirin B (LrB) is an active component isolated from *Sanguis draxonis*, which is a Chinese traditional herb also known as Dragon's Blood \[[@B128-ijms-21-03646]\]. Yuhao et al. \[[@B93-ijms-21-03646]\] investigated the effects of LrB on RANKL-induced osteoclast activity in vitro and in an OVX-induced osteoporosis mouse model in vivo. LrB attenuates RANKL-induced \[Ca^2+^\]~i~ oscillations, ROS production, and NFATc1 translocation into the nucleus in BMMs. Therefore, LrB can inhibit osteoclast differentiation and function by suppressing \[Ca^2+^\]~i~ oscillations, ROS, and NFATc1 activities. LrB also exerts a protective effect on OVX-induced osteoporosis in a mouse model \[[@B93-ijms-21-03646]\].

### 4.3.12. Calreticulin {#sec4dot3dot12-ijms-21-03646}

Calreticulin (CRT) is a Ca^2+^-binding protein that regulates intracellular Ca^2+^ homeostasis by modulating cytoplasmic and ER Ca^2+^ levels \[[@B129-ijms-21-03646],[@B130-ijms-21-03646],[@B131-ijms-21-03646]\]. Fischer et al. \[[@B94-ijms-21-03646]\] found that exogenous CRT has an anti-osteoclastogenic effect in vitro and in vivo. Recombinant CRT Inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations, but not ionomycin-induced Ca^2+^ influx in BMMs. Recombinant CRT also blocks expression of NFATc1 and c-Fos, but not CREB and NF-κB in RAW264.7 cells.

### 4.3.13. 6-Shogaol {#sec4dot3dot13-ijms-21-03646}

Shogaols are significant biomarkers used for the quality control of ginger-containing products and responsible for the pungent flavor in dried ginger. Among them, 6-shogaol is the most common type \[[@B132-ijms-21-03646]\]. The 6-shogaol inhibits RANKL-induced \[Ca^2+^\]~i~ oscillations, ROS production, and NFATc1 activities in BMMs. Furthermore, 6-shogaol attenuates osteoclastogenesis and alveolar bone resorption in a ligature-induced periodontitis model in vivo \[[@B95-ijms-21-03646]\].

4.4. Increasing \[Ca^2+^\]~i~ Oscillations {#sec4dot4-ijms-21-03646}
------------------------------------------

### Amyloid Beta Peptide

Amyloid beta peptide (Aβ) is the principal component of the accumulations of β-amyloid found in the brains of Alzheimer's patients \[[@B133-ijms-21-03646]\]. Various studies have addressed the role of Aβ in osteoclasts \[[@B134-ijms-21-03646],[@B135-ijms-21-03646],[@B136-ijms-21-03646]\]. Specifically, a recent study showed that Aβ enhances RANKL-induced osteoclast activation and functions through nuclear factor-κB inhibitor α (IκB-α) degradation, extracellular-signal-regulated kinase (ERK) phosphorylation, and increased \[Ca^2+^\]~i~ oscillations in BMMs \[[@B96-ijms-21-03646]\].

5. Closing Remarks and Perspectives {#sec5-ijms-21-03646}
===================================

The crucial studies on Ca^2+^ signaling in osteoclastogenesis have highlighted its role in bone biology. Considering the involvement of Ca^2+^ signaling in bone biology, the relatively few studies available to date suggest the importance of TRP channels for modulating osteoclastogenesis and bone loss. Therefore, most of the therapeutic potentials remain open. We estimate that pharmacological targeting of this membrane channels may result in the development of therapeutics that facilitate or inhibit Ca^2+^ influx.

J.H.H., D.M.S., and J.Y.K. contributed to conception and design of manuscript; J.Y.K. drafted the article and revised it critically for important intellectual contents; N.K. and Y.-M.Y. collected data; J.H.H. and D.M.S. contributed to final approval of the version to be published. All authors are accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government MSIT (2019R1F1A1046785 (to J.H.H.), 2020R1A2C2003409 (to D.M.S.)).

The authors declare no conflict of interest.

RANKL

receptor activator of nuclear factor-κB (NF-κB) ligand

M-CSF

macrophage colony-stimulating factor

NFATc1

nuclear factor of activated T cells

Ca

2+

calcium

TRAF6

tumor necrosis factor (TNF) receptor-associated factor 6

MAPKs

mitogen-activated protein kinases

NF-κB

nuclear factor-κB

AP-1

activator protein-1

PLCγ

phospholipase Cγ

IP

3

inositol 1, 4, 5-triphosphate

\[Ca

2+

\]

i

intracellular Ca

2+

concentration

ER

endoplasmic reticulum

SOCE

store-operated Ca

2+

entry

TRP

transient receptor potential

SERCA

Sarco/endoplasmic reticulum Ca

2+

-ATPase

ROS

reactive oxygen species

CaM

calmodulin

Homer2/3

Homer2 and Homer3

DKO

double-knockout

TRPCs

Transient receptor potential canonical channel

TRPVs

Transient receptor potential vanilloid channel

TRPMs

Transient receptor potential melastatin channel

TRPMLs

Transient receptor potential mucolipin channel

TRPPs

Transient receptor potential polycystin channel

TRPAs

Transient receptor potential ankyrin channel

I-mfa

inhibitor of MyoD family isoform a

I

CRAC

Ca

2+

release-activated Ca

2+

current

CB1/CB2

cannabinoid receptors type 1 and 2

PGE2

prostaglandin E2

SIRT1

Sirtuin 1

MM

multiple myeloma

STIM1

Stromal interaction molecule 1

FSS

fluid shear stress

siRNA

small interfering RNA

ERα

estrogen receptor α

CCN

Ca

2+

-Calcineurin-NFATc1

OVX

ovariectomized

BMMs

bone marrow--derived macrophages

OAA

Oleanolic acid acetate

LPS

lipopolysaccharide

HAR

Harpagoside

Btk

Bruton's tyrosine kinase

Syk

spleen tyrosine kinase

MG

Methyl gallate

TN

Tatarinan N

CaMK

Ca

2+

/calmodulin dependent protein kinase

CREB

cAMP-responsive element-binding protein

GH

Glechoma hederacea

VGCCs

voltage-gated Ca

2+

channels

PO

Portulaca oleracea

POEE

Portulaca oleracea

ethanol extract

MTX

Methotrexate

XAT

Xanthotoxin

CaMKK

Calmodulin-dependent protein kinase kinase

Pyk2

Proline-rich tyrosine kinase 2

SIN

Sinomenine

RA

rheumatoid arthritis

TNF-α

tumor necrosis factor-α

CSA

Cajaninstilbene acid

APO

apocynin

NOX

NADPH oxidase

TPC2

two pore segment channel 2

IP

3

R1

inositol 1,4,5-triphosphate receptor type 1

LrB

Loureirin B

CRT

Calreticulin

Aβ

Amyloid beta peptide ()

IκB-α

nuclear factor-κB inhibitor α

ERK

extracellular-signal-regulated kinase

![Schematic illustration of Ca^2+^ signaling in osteoclastogenesis. (**A**) RANK on the surface of osteoclast progenitor activates signaling by RANKL on the surface of osteoblasts/stromal cell to promote osteoclastogenesis. (**B**) Osteoclast precursor stage. In the early stages of osteoclastogenesis, RANK-bound RANKL induces activation of TRAF6 and stimulates PLCγ. PLCγ produces IP~3~, which evokes Ca^2+^ release from the ER. In addition, RANK-bound RANKL induces lysosomal Ca^2+^ release through TRPML1 and generates Ca^2+^ oscillation. SOCE, VGCC and TRPV2 are also involved in Ca^2+^ oscillation. The Ca^2+^ oscillations induce Ca^2+^-calcineurin-NFATc1 signaling. In the late stages of osteoclastogenesis, the Ca^2+^ oscillation is sustained by TRPV4-mediated Ca^2+^ influx. In the nucleus, NFATc1 induces the expression of various osteoclast-specific genes. (**C**) In mature osteoclasts, TRPV4 and TRPV5 in the basolateral membrane are necessary for the regulation of osteoclastic bone resorption. TRPV5 is predominantly located on the ruffled border of resorbing osteoclasts. Abbreviations: RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand; RANK, receptor activator of nuclear factor-κB (NF-κB); NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAF6, tumor necrosis factor (TNF) receptor-associated factor 6; PLCγ, phospholipase Cγ; IP~3~, inositol 1,4,5-triphosphate; ER, endoplasmic reticulum; Ca^2+^, calcium; \[Ca^2+^\]~i~, intracellular Ca^2+^ concentration; SOCE, store-operated Ca^2+^ entry; VGCC, voltage-gated Ca^2+^ channel; TRPV2, transient receptor potential vanilloid 2; TRPV4, transient receptor potential vanilloid 4; TRPV5, transient receptor potential vanilloid 5; TRPML1, transient receptor potential mucolipin 1.](ijms-21-03646-g001){#ijms-21-03646-f001}

![The schematic illustration summarized diverse compounds that regulate Ca^2+^ signaling in osteoclastogenesis. KMUP-1 (7-\[2-\[4-(2-chlorophenyl)piperazinyl\]ethyl\]-1,3-dimethylxanthine), Zinc, Praeruptorin A, Cyanidin Chloride, Lumichrome and *Asiaticoside* inhibit osteoclastogenesis via inhibiting Ca^2+^-Calcineurin-NFATc1 signaling independent of PLCγ. Methotrexate (MTX), Xanthotoxin (XAT), Sinomenine (SIN), Dried plum fractions, KN93, Cajaninstilbene acid (CSA), Methylglyoxal, Apocynin (APO), Loureirin B (LrB), Calreticulin (CRT) and 6-Shogaol inhibit osteoclastogenesis via decreasing \[Ca^2+^\]~i~. On the contrary, Amyloid beta peptide (Aβ) enhances osteoclastic bone resorption by increasing \[Ca^2+^\]~i~ oscillations, resulting in upregulation of NFATc1. *Portulaca oleracea* (PO) inhibits osteoclastogenesis by inhibiting Ca^2+^ release from intracellular Ca^2+^ stores. Oleanolic acid acetate (OAA), Artesunate, Berberine and Physalin D inhibit osteoclastogenesis via inhibiting PLCγ-Ca^2+^-NFATc1 signaling. Harpagoside (HAR) inhibits osteoclastogenesis via inhibiting Syk-Btk-PLCγ-Ca^2+^ Signaling. Methyl gallate (MG) and Tatarinan N (TN) inhibit osteoclastogenesis by suppression of Btk-PLCγ cascade. *Glechoma hederacea* (GH) inhibits osteoclastogenesis by inactivating VGCCs independent of Ca^2+^ release from intracellular Ca^2+^ stores. Abbreviations: RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand; RANK, receptor activator of nuclear factor-κB (NF-κB); NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAF6, tumor necrosis factor (TNF) receptor-associated factor 6; MAPK, mitogen-activated protein kinases; AP-1, activator protein-1; Btk, Bruton's tyrosine kinase; Syk, spleen tyrosine kinase; PLCγ, phospholipase Cγ; IP3R, inositol 1,4,5-triphosphate receptor; ER, endoplasmic reticulum; Ca^2+^, calcium; \[Ca^2+^\]~i,~ intracellular Ca^2+^ concentration; SOCE, store-operated Ca^2+^ entry; VGCC, voltage-gated Ca^2+^ channel; TRP channels, transient receptor potential cation channels; CaMKs, Ca^2+^/calmodulin dependent protein kinases; CREB, cAMP-responsive element-binding protein; CaM, calmodulin.](ijms-21-03646-g002){#ijms-21-03646-f002}
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###### 

Diverse compounds that regulate Ca^2+^ signaling in osteoclastogenesis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                                                             Mechanism of Inhibition of RIO ^(1)^                                                                                                               Species                 Administered Dose   Ref                 
  -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------- ------------------- --------------------------
  **Mode of action: Ca^2+^-Calcineurin-NFATc1(CCN ^(2)^) signaling**                                                                                                                                                                                                                      

  KMUP-1                                                               CCN signaling independently of PLCγ                                                                                                                RAW264.7 cell,\         1--10 μM            1, 5, 10 mg/kg      \[[@B70-ijms-21-03646]\]
                                                                                                                                                                                                                          BALB/c mice                                                     

  Zinc                                                                 CCN signaling independently of PLCγ                                                                                                                RAW264.7 cell,\         10--100 μM          N/A ^(4)^           \[[@B71-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice)                                             

  Praeruptorin A                                                       Inhibition of PLCγ-independent \[Ca^2+^\]~i~ oscillations                                                                                          BMMs (ICR mice)         10 μM               N/A                 \[[@B72-ijms-21-03646]\]

  Cyanidin Chloride                                                    Suppression of NF-κB, ERK and CCN signaling                                                                                                        RAW264.7 cell,\         5--10 μM            5 mg/kg             \[[@B73-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  Lumichrome                                                           Suppression of NF-κB, MAPK and CCN signaling                                                                                                       RAW264.7 cell,\         7.5--10 μM          7.5 mg/kg           \[[@B74-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  *Asiaticoside*                                                       Suppression of NF-κB and CCN signaling                                                                                                             RAW264.7 cell,\         2.5--20 μM          N/A                 \[[@B75-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice)                                             

  **Mode of action: PLCγ- Ca^2+^-NFATc1(PCN ^(3)^) signaling**                                                                                                                                                                                                                            

  OAA                                                                  PCN signaling                                                                                                                                      BMMs (ICR mice),\       20 μM               10 mg/kg            \[[@B76-ijms-21-03646]\]
                                                                                                                                                                                                                          ICR mice                                                        

  HAR                                                                  Syk-Btk-PLCγ- Ca^2+^ Signaling                                                                                                                     BMMs (ICR mice),\       25--100 μM          10 mg/kg            \[[@B77-ijms-21-03646]\]
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  Artesunate                                                           PCN signaling                                                                                                                                      RAW264.7 cell,\         3.125--12.5 μM      5, 30 mg/kg         \[[@B78-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  MG                                                                   Akt and Btk-PLCγ- Ca^2+^ Signaling                                                                                                                 BMMs (ICR mice),\       1--10 μM            10 mg/kg            \[[@B79-ijms-21-03646]\]
                                                                                                                                                                                                                          ICR mice                                                        

  Berberine                                                            \* Inhibition of LPS-induced osteoclastogenesis through TRAF6 and PCN signaling                                                                    RAW264.7 cell           5--20 μM            N/A                 \[[@B80-ijms-21-03646]\]

  TN                                                                   Suppression of Btk-PLCγ cascade, NF-κB, MAPKs and CCN signaling                                                                                    BMMs (C57BL/6 mice)     1.25--5 μM          N/A                 \[[@B81-ijms-21-03646]\]

  Physalin D                                                           Suppression of PLCγ-CaMK-CREB pathway                                                                                                              BMMs (C57BL/6 mice),\   5 μM                10, 100 mg/kg       \[[@B82-ijms-21-03646]\]
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  **Mode of action: Negative regulation of Ca^2+^ signaling**                                                                                                                                                                                                                             

  GH                                                                   Abrogation of RANKL-induced \[Ca^2+^\]~i~ oscillations by inactivating VGCCs independently of Ca^2+^ release from intracellular Ca^2+^ stores      BMMs (C57BL/6 mice)     5--50 μg/mL         N/A                 \[[@B83-ijms-21-03646]\]

  PO                                                                   Suppression of RANKL-induced \[Ca^2+^\]~i~ oscillations by inhibiting Ca^2+^ release from intracellular Ca^2+^ stores                              murine BMMs             50 μg/mL            N/A                 \[[@B84-ijms-21-03646]\]

  MTX                                                                  Decrease of RANKL-induced Ca^2+^ influx                                                                                                            BMMs (C57BL/6 mice)     1, 5 μM             N/A                 \[[@B85-ijms-21-03646]\]

  XAT                                                                  Suppression of RANKL-induced \[Ca^2+^\]~i~ oscillations and Ca^2+^-CaMKK-PYK2 signaling                                                            BMMs (C57BL/6 mice),\   0.1, 1 μM           0.5, 5 mg/kg        \[[@B86-ijms-21-03646]\]
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  SIN                                                                  \* Inhibition of LPS-induced osteoclastogenesis by decreasing expression of NF-κB, AP-1 and Ca^2+^-NFATc1                                          RAW264.7 cell,\         0.25--1 mM          25, 50, 100 mg/kg   \[[@B87-ijms-21-03646]\]
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  Dried plum fractions                                                 Suppression of MAPKs and Ca^2+^ signaling, resulting in inhibition of NFATc1                                                                       RAW264.7 cell,\         1, 10 μg/mL         N/A                 \[[@B88-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice)                                             

  KN93                                                                 Decreasing of \[Ca^2+^\]~i~                                                                                                                        RAW264.7 cell           10 μM               N/A                 \[[@B89-ijms-21-03646]\]

  CSA                                                                  Block of ROS activity and \[Ca^2+^\]~i~ oscillations                                                                                               RAW264.7 cell,\         5--10 μM            10 mg/kg            \[[@B90-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  Methylglyoxal                                                        Suppression of \[Ca^2+^\]~i~, mitochondrial biogenesis, mitochondrial membrane potential, and glyoxalase I                                         RAW264.7 cell           10--200 μM          N/A                 \[[@B91-ijms-21-03646]\]

  APO                                                                  Decreasing of \[Ca^2+^\]~i~                                                                                                                        BMMs (C57BL/6 mice)     1 μM                N/A                 \[[@B92-ijms-21-03646]\]

  LrB                                                                  Suppression of \[Ca^2+^\]~i~ oscillations, ROS production, and NFATc1 translocation                                                                RAW264.7 cell,\         5--10 μM            4 mg/kg             \[[@B93-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  CRT                                                                  Suppression of RANKL-induced \[Ca^2+^\]~i~ oscillations and expression of NFATc1 and c-Fos, independently of ionomycin-induced Ca^2+^ influx       RAW264.7 cell,\         0.5--500 ng/ml      0.2 mg/kg           \[[@B94-ijms-21-03646]\]
                                                                                                                                                                                                                          BMMs (C57BL/6 mice),\                                           
                                                                                                                                                                                                                          C57BL/6, NOD mice,                                              

  6-Shogaol                                                            Suppression of \[Ca^2+^\]~i~ oscillations, ROS production, and NFATc1 activity                                                                     BMMs (C57BL/6 mice),\   2.5--10 μM          10 mg/kg            \[[@B95-ijms-21-03646]\]
                                                                                                                                                                                                                          C57BL/6 mice                                                    

  **Mode of action: Increasing \[Ca^2+^\]~i~ oscillations**                                                                                                                                                                                                                               

  Aβ                                                                   \* Enhancement of osteoclast activation by activating NF-κB, ERK and increasing \[Ca^2+^\]~i~ oscillations, resulting in upregulation of NFAT-c1   BMMs (C57BL/6 mice)     1--10 μM            N/A                 \[[@B96-ijms-21-03646]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Another mechanism besides RIO, Abbreviations: (1) RIO, RANKL-induced osteoclastogenesis; (2) CCN, Ca^2+^-Calcineurin-NFATc1; (3) PCN, PLCγ- Ca^2+^-NFATc1; (4) N/A, not applicable; The other abbreviations are listed in the last paragraph.
